Sequenom, Inc. (NASDAQ:SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, announced today the appointment of Dirk van den Boom, Ph.D. to the position of interim President and Chief Executive Officer. Dr. van den Boom succeedsWilliam J. Welch following his resignation from that role, and as a director, to pursue other interests. In addition, Dr. van den Boom will continue to serve as Sequenom’s Chief Scientific and Strategy Officer.
Prior to his appointment as Interim President and CEO, Dr. van den Boom served as Chief Scientific and Strategy Officer since June 2014, and before that as Executive Vice President, Research and Development and Chief Technology Officer beginning in December 2012. Dr. van den Boom joined Sequenom in 1998 at the Company’s Hamburg office, subsequently serving in various management roles of increasing responsibility.
“We are excited for Dirk to take on the role of interim President and Chief Executive Officer, and believe that he is well positioned to lead our key strategic initiatives to develop and commercialize innovative products and services at Sequenom,” said Kenneth F. Buechler, Ph.D., Chairman of the Board of Directors. “We are confident that he will successfully lead our efforts to capitalize on our company’s future growth opportunities and goals. We thank Bill for his efforts for the Company and wish him well in future endeavors.” (Original Source)
Shares of Sequenom closed last Friday at $2.38. SQNM has a 1-year high of $4.80 and a 1-year low of $1.82. The stock’s 50-day moving average is $2.22 and its 200-day moving average is $3.27.
On the ratings front, Sequenom has been the subject of a number of recent research reports. In a report issued on September 18, William Blair analyst Brian Weinstein reiterated a Buy rating on SQNM. Separately, on August 4, Wedbush’s Zarak Khurshid maintained a Hold rating on the stock and has a price target of $3.50.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Brian Weinstein and Zarak Khurshid have a total average return of 9.4% and 1.0% respectively. Weinstein has a success rate of 56.0% and is ranked #1000 out of 3765 analysts, while Khurshid has a success rate of 60.8% and is ranked #1908.
Sequenom Inc is a molecular diagnostic testing and genetics analysis company which provides molecular diagnostic testing services.